PriceTargets.com logo

Unicycive Therapeutics - UNCY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.13
  • Forecasted Upside: 632.67%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$0.70 As of 12/17/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for UNCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Unicycive Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UNCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UNCY

Analyst Price Target is $5.13
▲ +632.67% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Unicycive Therapeutics in the last 3 months. The average price target is $5.13, with a high forecast of $9.00 and a low forecast of $2.50. The average price target represents a 632.67% upside from the last price of $0.70.

This chart shows the closing price for UNCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Unicycive Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/22/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00
11/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50
10/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50
9/6/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50
8/15/2024HC WainwrightLower TargetBuy ➝ Buy$4.50 ➝ $2.50
7/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.50 ➝ $4.50
7/9/2024Brookline Capital ManagementUpgradeStrong-Buy
6/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.50 ➝ $4.50
5/31/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00
5/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.50 ➝ $4.50
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.50
4/15/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00
4/4/2024Piper SandlerInitiated CoverageOverweight$9.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.50
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.50
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.50
2/14/2024Noble FinancialInitiated CoverageOutperform$6.00
12/19/2023HC WainwrightReiterated RatingBuy ➝ Buy$4.50
12/4/2023BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00
8/16/2023HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $4.50
7/3/2023Maxim GroupLower Target$6.00 ➝ $4.00
6/30/2023HC WainwrightLower TargetBuy$8.00 ➝ $7.00
4/6/2023Roth CapitalReiterated RatingBuy
4/3/2023HC WainwrightReiterated RatingBuy$8.00
3/31/2023EF Hutton Acquisition Co. IReiterated RatingBuy$24.00
3/9/2023HC WainwrightReiterated RatingBuy$8.00
3/9/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$5.00
3/8/2023Maxim GroupBoost TargetBuy$3.00 ➝ $6.00
11/28/2022HC WainwrightLower TargetBuy$9.00 ➝ $8.00
6/8/2022HC WainwrightInitiated CoverageBuy$9.00
3/16/2022Maxim GroupInitiated CoverageBuy$3.00
8/17/2021BenchmarkInitiated CoverageBuy
8/9/2021Roth CapitalInitiated CoverageBuy$13.50
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Unicycive Therapeutics logo
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Read More

Today's Range

Now: $0.70
Low: $0.66
High: $0.72

50 Day Range

MA: $0.55
Low: $0.36
High: $0.80

52 Week Range

Now: $0.70
Low: $0.20
High: $1.82

Volume

1,245,265 shs

Average Volume

1,248,704 shs

Market Capitalization

$72.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Unicycive Therapeutics?

The following Wall Street research analysts have issued reports on Unicycive Therapeutics in the last year: Benchmark Co., Brookline Capital Management, HC Wainwright, Noble Financial, and Piper Sandler.
View the latest analyst ratings for UNCY.

What is the current price target for Unicycive Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Unicycive Therapeutics in the last year. Their average twelve-month price target is $5.13, suggesting a possible upside of 632.7%. Piper Sandler has the highest price target set, predicting UNCY will reach $9.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.50 for Unicycive Therapeutics in the next year.
View the latest price targets for UNCY.

What is the current consensus analyst rating for Unicycive Therapeutics?

Unicycive Therapeutics currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UNCY will outperform the market and that investors should add to their positions of Unicycive Therapeutics.
View the latest ratings for UNCY.

What other companies compete with Unicycive Therapeutics?

Other companies that are similar to Unicycive Therapeutics include Larimar Therapeutics, Amylyx Pharmaceuticals, Lifecore Biomedical, iTeos Therapeutics and Benitec Biopharma. Learn More about companies similar to Unicycive Therapeutics.

How do I contact Unicycive Therapeutics' investor relations team?

Unicycive Therapeutics' physical mailing address is 5150 EL CAMINO REAL SUITE A-32, LOS ALTOS CA, 94022. The company's listed phone number is 650-351-4495 and its investor relations email address is [email protected]. The official website for Unicycive Therapeutics is www.unicycive.com. Learn More about contacing Unicycive Therapeutics investor relations.